Novo Nordisk tumbles as Wegovy sales miss, trial setback overshadow raised outlook
Investing.com — Novo Nordisk (CSE:NOVOb) (NYSE:NVO) hiked its full-year guidance, saying annual sales and operating profit should decline…
Browsing Tag